Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia

BMC Public Health

Volumn 16, Issue 1, 2016, Pages

  Jamotte, Aurélien ^a   Chong, Chui Fung ^b,f   Manton, Andrew ^c   Macabeo, Bérengère ^d   Toumi, Mondher ^a,e  

^a CREATIV CEUTICAL   (France)

^b Asia and JPAC Region   (Singapore)

^c Regulation and Policy   (Australia)

^d SANOFI PASTEUR   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f Pte Ltd   (Singapore)

Author keywords

Australia; Benefit; Cost; Influenza; Public health; Quadrivalent; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PRESCHOOL CHILD; PUBLIC HEALTH; THEORETICAL MODEL; VACCINATION; VICTORIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, THEORETICAL; PUBLIC HEALTH; VACCINATION; VICTORIA; YOUNG ADULT;

EID: 84979300047     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-016-3297-1     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention (CDC). People at High Risk of Developing Flu-Related Complications. http://www.cdc.gov/flu/about/disease/high-risk.htm. Accessed 01 Mar 2016.
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2004;53:1-40.
3. Newall AT, Scuffham PA. Influenza-related disease: the cost to the Australian healthcare system. Vaccine. 2008;26:6818-23.
4. World Health Organization (WHO). Influenza Fact sheet n°211. 2014. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 01 Mar 2016.
5. Centers for Disease Control and Prevention (CDC). Vaccine Effectiveness - How well does the flu vaccine work ? http://www.cdc.gov/flu/about/qa/vaccineeffect.htm. Accessed 01 Mar 2016.
6. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2015 update). Canberra: Australian Government Department of Health; 2015.
7. Australian Government Department of Health. Immunise Australia Program. National Immunisation Program 2015 seasonal flu shot. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-influenza. Accessed 15 Jan 2016.
8. World Health Organization (WHO). Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87:461-76.
9. Commission of the European Communities. Council recommendation on seasonal influenza vaccination. 2009.
10. Centers for Disease Control and Prevention (CDC). CDC's Advisory Committee on Immunization Practices (ACIP) Recommends Universal Annual Influenza Vaccination. 2010. http://www.cdc.gov/media/pressrel/2010/r100224.htm. Accessed 01 Mar 2016.
11. WHO recommendations on the composition of influenza virus vaccines 2002-2012. http://www.who.int/influenza/vaccines/virus/recommendations/en/. Accessed 01 Mar 2016.
12. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs. 2012;72:2177-85.
13. Jennings Z, Carter I, McPhie K, Kok J, Dwyer DE. Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. Eurosurveillance. 2015. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21201. Accessed 18 Jul 2016.
14. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.
15. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49-57.
16. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993-8.
17. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012;30:7443-6.
18. Therapeutic Good Administration (TGA). 2015 seasonal influenza vaccines. 2015. https://www.tga.gov.au/media-release/2015-seasonal-influenza-vaccines. Accessed 02 Mar 2016.
19. Australian Bureau of Statistics (ABS). Australian Health Survey 2011-2013. http://www.abs.gov.au/australianhealthsurvey. Accessed 02 Mar 2016.
20. Russel ME, Snell R, Thompson D, May E, Stewart S. Uncovering the burden of angina pectoris in Australia. Heart Lung Circ. 2004;13:S62-S3.
21. Katzenellenbogen JM, Sanfilippo FM, Hobbs MS, Briffa TG, Ridout SC, Knuiman MW, et al. Variable effects of prevalence correction of population denominators on differentials in myocardial infarction incidence: a record linkage study in aboriginal and non-aboriginal Western Australians. J Clin Epidemiol. 2011;64:658-66.
22. Australian Bureau of Statistics (ABS). Australian Demographic Statistics. 2012. http://www.abs.gov.au/AUSSTATS/absat.nsf/DetailsPage/3101.0Dec%202012?OpenDocument. Accessed 02 Mar 2016.
23. Jefferson T, Rivetti A, Di PC, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;8:CD004879.
24. Jefferson T, Di PC, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269.
25. Jefferson T, Di PC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876.
26. Australian Government Department of Health. Annual report of the National Notifiable Diseases Surveillance System. https://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-nndssar.htm. Accessed 01 Mar 2016.
27. World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza. http://www.influenzacentre.org/. Accessed 01 Mar 2016.
28. World Health Organization (WHO). FluNet. Laboratory confirmed data from the Global Influenza Surveillance and Response System (GISRS). http://www.who.int/influenza/gisrs
29. Australian Institute of Health and Welfare (AIHW). 2009 Adult Vaccination Survey: summary results. http://www.aihw.gov.au/publication-detail/?id=10737418409. Accessed 02 Mar 2016.
30. Newcombe J, Kaur R, Wood N, Seale H, Palasanthiran P, Snelling T. Prevalence and determinants of influenza vaccine coverage at tertiary pediatric hospitals. Vaccine. 2014;32:6364-8.
31. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10:1171-80.
32. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-96.
33. Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine. 2008;26:2135-41.
34. Australian Government Department of Health. Medicare Benefits Schedule. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home. Accessed 02 Mar 2016.
35. The Independent Hospital Pricing Authority (IHPA). National Hospital Cost Data Collection Australian Public Hospitals Cost Report 2011-2012, Round 16. https://www.ihpa.gov.au/publications/nhcdc-australian-public-hospitals-cost-report-2011-2012-round-16. Accessed 01 Mar 2016.
36. Australian Institute of Health and Welfare (AIHW). Australian refined diagnosis-related groups (AR-DRG) data cubes 2011-12 to 2012-13. http://www.aihw.gov.au/hospitals-data/ar-drg-data-cubes/. Accessed 01 Mar 2016.
37. Australian Bureau of Statistics (ABS). Consumer Price Index. http://www.abs.gov.au/AUSSTATS/absat.nsf/DetailsPage/6401.0Sep%202014?OpenDocument. Accessed 02 Mar 2016.
38. Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le GC, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med. 2002;162:1842-8.
39. Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect. 2011;62:379-87.
40. Australian Bureau of Statistics (ABS). Labour Force. 2014. http://www.abs.gov.au/AUSSTATS/absat.nsf/DetailsPage/6202.0May%202014?OpenDocument. Accessed 02 Mar 2016.
41. Australian Bureau of Statistics (ABS). Employee Earnings and Hours, Australia, May 2014. http://www.abs.gov.au/AUSSTATS/absat.nsf/Latestproducts/6306.0Main%20Features2May%202014?opendocument&tabname=Summary&prodno=6306.0&issue=May%202014&num=&view=. Accessed 02 Mar 2016.
42. Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One. 2011;6:e22308.
43. O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113:585-93.
44. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846-55.
45. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. Elife. 2015;4:e05055.
46. Milne GJ, Halder N, Kelso JK, Barr IG, Moyes J, Kahn K, et al. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study. Influenza Other Respir Viruses. 2016;10(4):324-32.
47. Van Bellinghen LA, Meier G, Van VI. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9:e98437.
48. van Doorslaer E, Masseria C, Koolman X, Group OHER. Inequalities in access to medical care by income in developed countries. CMAJ. 2006;174:177-83.
49. Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813.
50. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26:911-24.
51. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28 Suppl 4:D45-53.
52. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-8.
53. Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses. 2012;6:37-43.
54. World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2008. http://apps.who.int/iris/bitstream/10665/69981/1/WHO-IVB-08.14-eng.pdf. Accessed 29 Apr 2016.
55. Australian Department of Health. National notifiable diseases surveillance annual reports 2002-2012. 2015.